pp-212 Tablets

Indication: Alzheimer's disease — targeting neuroinflammation in early-to-moderate AD Clinical stage: Phase 2 — approved by Taiwan FDA (TFDA) September 2023; Phase 2 trial ongoing Modality: Small molecule (selective, brain-penetrant CSF-1R inhibitor) Mechanism / Target: Selective inhibitor of colony stimulating factor 1 receptor (CSF-1R) with good blood-brain barrier penetration; specifically suppresses activated microglia by blocking CSF-1R-driven microglial proliferation and pro-inflammatory activation; reduces neuroinflammation-related gene expression (TREM2, Iba1) while preserving normal microglial surveillance function Route / form: Oral tablet/capsule Differentiation: First brain-penetrant CSF-1R inhibitor targeting neuroinflammation in Alzheimer's — a mechanism entirely distinct from amyloid/tau approaches;